A retrospective cohort study analyzed patients with multiple myeloma (MM) refractory to anti-CD38 monoclonal antibody therapy, involving 663 patients, with a focus on those with triple class refractory (TCR) disease. The study, using data from the Canadian Myeloma Research Group Database, found that among patients who received further treatment after anti-CD38 mAb therapy failure, the median progression-free survival (PFS) and overall survival (OS) were 4.6 and 13.3 months, respectively. For TCR patients, these figures were even lower at 4.4 and 10.5 months.

This research highlighted the significant gap in outcomes for MM patients post-anti-CD38 mAb therapy, showcasing the limitations of current standard of care (SoC) treatments. Despite the variety of available therapies, outcomes remained poor, especially for TCR patients, reflecting the critical need for better treatment options and advancements in care for this challenging subgroup. The study aligns with global research, stressing the urgency for new therapeutic developments to improve prognosis and guide future clinical strategies for this incurable condition.

Reference: Visram A, De La Torre A, White D, et al. Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database. Blood Cancer J. 2023 Dec 8;13(1):181. doi: 10.1038/s41408-023-00946-z. PMID: 38065967; PMCID: PMC10709576.